Patient experience of brand transition for homecare biologics
Research type
Research Study
Full title
Patient experience of brand transition for homecare biologics
IRAS ID
257530
Contact name
Fraser Cummings
Contact email
Sponsor organisation
University Hospital Southampton NHS Foundation Trust
Duration of Study in the UK
0 years, 2 months, 22 days
Research summary
Adalimumab is a biological medicine used for a range of inflammatory disease. Biosimilar brands of this medicine are now available, often at a lower cost, and expected to have similar effectiveness and side effects as the original brand (Humira). Understandably, some patients have concerns about transitioning between brands. The researcher intends to do a small pilot study interviewing up to 5 patients who have been through the switching process to understand what concerns these patients have and whether there is any way we could improve the information that we use to inform patients of these brand transitions or the process that we use.
REC name
South West - Frenchay Research Ethics Committee
REC reference
19/SW/0155
Date of REC Opinion
6 Feb 2020
REC opinion
Further Information Favourable Opinion